Document is current
Any future updates will be listed below
-
Authors
Nabbi, Arash https://orcid.org/0000-0002-3195-7361
Danesh, Arnavaz
Espin-Garcia, Osvaldo
Pedersen, Stephanie
Wellum, Johanna
Fu, Lingyan Helen
Paulson, Joseph N.
Geoerger, Birgit https://orcid.org/0000-0003-4361-3643
Marshall, Lynley V.
Trippett, Tanya
Rossato, Gianluca
Pugh, Trevor J. https://orcid.org/0000-0002-8073-5888
Hutchinson, Katherine E. https://orcid.org/0000-0002-4660-3523
-
Funding
Funding for this research was provided by:
Genentech
- License Information
-
More Information
Article History
Received: 3 August 2022
Accepted: 24 February 2023
First Online: 10 April 2023
Competing interests
: K.E.H., G.R., L.H.F. and J.N.P. are employees and stockholders of Roche/Genentech. T.J.P. has consulted for Illumina, Merck, AstraZeneca, PACT Pharma, Chrysalis Biomedical Advisors and the Canadian Pension Plan Investment Board (compensated); and receives research support (institutional) from Roche/Genentech. B.G. reports travel and accommodation expenses for attendance at a Roche-sponsored advisory board for atezolizumab. L.V.M. has provided consultation for Bayer, BMS, Tesaro and Illumina. T.T. reports consultancy fees from Roche/Genentech for advisory board attendance and previous protocol management activities from POETIC Data and Coordinating Center outside of the submitted work. All other authors have no competing interests.
